吉林敖东：公司密切关注集采常态化下仿制药的市场竞争格局

Core Viewpoint - The company is actively monitoring the competitive landscape of generic drugs under the normalized centralized procurement and is advancing its R&D projects in various therapeutic areas including cancer, kidney disease, diabetes, and cardiovascular diseases [2] Group 1: R&D Strategy - The company is focusing on the development of new products and the secondary development of major varieties to enhance its R&D capabilities [2] - It is strategically investing in drug development across multiple therapeutic fields [2] Group 2: Financial Strategy - The company is leveraging a dual-driven model of "pharmaceutical health + financial capital" to reinvest financial returns into its pharmaceutical core business [2] - It plans to reasonably allocate R&D investments based on actual development needs to steadily advance its R&D efforts [2] Group 3: Market Positioning - The company is positioning itself to improve its core competitiveness in the pharmaceutical industry through continuous R&D advancements [2]